{
    "2021-02-22": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Jim Simons' Firm's Top Trades of the 4th Quarter",
                "features": {
                    "keywords": [
                        "Simons",
                        "Firm",
                        "Top Trades",
                        "4th Quarter"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-03-15",
                "original_text": "AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Clinical Benefit",
                        "Late-Stage",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-15",
                "original_text": "Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients",
                "features": {
                    "keywords": [
                        "Phase 3",
                        "Induction Study",
                        "Upadacitinib",
                        "RINVOQ™",
                        "Clinical",
                        "Endoscopic",
                        "Histologic Outcomes",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-06-10",
                "original_text": "3 Stocks to Buy with Dividends Yielding More than 4%",
                "features": {
                    "keywords": [
                        "Stocks",
                        "Buy",
                        "Dividends",
                        "Yielding",
                        "4%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}